Complement Activation by gp160 Glycoprotein of HIV-1
Authors:
- Nicole Haeffner-CavaillonNHNicole Haeffner-Cavaillon
- Laurence WeissLWLaurence Weiss
- Francoise MailletFMFrancoise Maillet
- Michel D. KazatchkineMKMichel D. Kazatchkine
- 1 March 1993
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 9 (3) , 229-233
Abstract
The ability of the gp160 envelope glycoprotein of HIV-1 to activate human complement and to bind C3 fragments was investigated by incubating mammalian-derived recombinant gp 160 with seronegative serum and by quantitating the binding of C3b/iC3b to the protein using a biotinylated monoclonal antibody directed against a neoepitope expressed by cleaved human C3. Recombinant gp160 activated complement in a dose- and time-dependent fashion. Complement activation occurred through the classical pathway, independently of antibodies, and required C1q. Binding of anti-HIV IgG to rgp160 prior to exposure of the envelope glycoprotein to serum resulted in enhanced complement activation. Complexes of rgp120 with anti-HIV IgG also cleaved C3 in serum, resulting in deposition of C3b on gp120. These results provide a basis for C3-mediated facilitation of viral entry into target cells expressing receptors for fragments of human C3.Keywords
This publication has 3 references indexed in Scilit:
- Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell lineJournal of Virology, 1991
- Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysisJournal of Virology, 1990
- Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1Journal of Virology, 1990